CADL
NASDAQCandel Therapeutics Inc.
News · 26 weeks43-85%
2025-12-142026-06-07
Mix2590d
- Other11(44%)
- SEC Filings8(32%)
- Insider3(12%)
- Earnings2(8%)
- Analyst1(4%)
Latest news
25 items- PRCandel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate CancerPeer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with curative intent combined with aglatimagene besadenovec (aglatimagene) plus valacyclovir compared to placebo plus valacyclovirFindings support that addition of aglatimagene to standard-of-care radiotherapy can provide a meaningful benefit without increasing clinically significant toxicity Data reported in this publication will support planned Biologics License Application (BLA) submission for aglatimagene in fourth quarter of 2026 NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Thera
- PRCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on May 31, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to three new employees, stock options to purchase an aggregate of 63,000 shares of the Company's common stock, with a per share exercise price of $8.30. The inducement stock options were made under the Company's 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying t
- SECCandel Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
- PRCandel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual MeetingExtended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific disease-free survival (DFS) of 39% after aglatimagene administration compared to placebo, reinforcing the potential of aglatimagene to reduce the risk of tumor recurrence in men receiving radiotherapy for localized disease.Clinical benefit demonstrated in the intention-to treat (ITT) population by secondary and clinically relevant exploratory endpoints with numerical improvements observed in time to biochemical failure (TTBF), lower incidence of and increased time to metastase
- SECSEC Form SCHEDULE 13G filed by Candel Therapeutics Inc.SCHEDULE 13G - Candel Therapeutics, Inc. (0001841387) (Subject)
- SECSEC Form 10-Q filed by Candel Therapeutics Inc.10-Q - Candel Therapeutics, Inc. (0001841387) (Filer)
- SECCandel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
- PRCandel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsCompany plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026Announced purpose-built commercial partnership with EVERSANA® to support potential U.S. launch of aglatimagene in localized prostate cancerCompany reported extended survival tail observed in trial of aglatimagene in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI)Company to report extended follow-up data from the positive phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer at the America
- PRCandel Therapeutics to Present at Upcoming Investor ConferencesNEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present and participate in one-on-one meetings with investors at upcoming investor conferences. Stifel 2026 Virtual Targeted Oncology Forum Date/ Time: Wednesday, May 20, 2026, at 10 AM ETWebcast Link: Stifel / Candel Presentation 2026 Jefferies Global Healthcare Conference (New York, NY)Date/Time: Wednesday, June 3, 2026, at 5:3
- PRCandel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual MeetingConference Call Scheduled for Friday, May 15, 2026, at 1:00 PM ET NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced that Candel's management will host a webcast and conference call on Friday, May 15, 2026 at 1:00 PM ET. The call will discuss the Company's extended follow-up data from the phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with intermediate- to high-risk localized prostate cancer. The discussion will follow the oral plena
- PRCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEEDHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients with cancer, today announced that on April 30, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 29,400 shares of the Company's common stock, with a per share exercise price of $6.18. The inducement stock options were made under the Company's 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying the award on th
- SECSEC Form DEFA14A filed by Candel Therapeutics Inc.DEFA14A - Candel Therapeutics, Inc. (0001841387) (Filer)
- SECSEC Form DEF 14A filed by Candel Therapeutics Inc.DEF 14A - Candel Therapeutics, Inc. (0001841387) (Filer)
- PRCandel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate CancerEVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026 NEEDHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to help patients with cancer, today announced that it entered into a product commercialization agreement (the "Agreement") with EVERSANA®, a leading provider of global commercialization services to the life sciences industry, to support the potential U.S. commercial launch of aglatimagene besadenovec (aglatimagene or CAN-2409
- ANALYSTCantor Fitzgerald initiated coverage on Candel TherapeuticsCantor Fitzgerald initiated coverage of Candel Therapeutics with a rating of Overweight
- INSIDERSEC Form 4 filed by Manning Paul B4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Papa Joseph C4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Loggia Nicoletta4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- PRCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEEDHAM, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on March 31, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to five new employees, stock options to purchase an aggregate of 70,000 shares of the Company's common stock, with a per share exercise price of $4.90. The inducement stock options were made under the Company's 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying the award o
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Candel Therapeutics Inc.SCHEDULE 13D/A - Candel Therapeutics, Inc. (0001841387) (Subject)
- PRCandel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint InhibitorsExtended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene besadenovec (aglatimagene or CAN-2409) surviving beyond 24 months, despite prior inadequate response to immune checkpoint inhibitors (ICI) and multiple adverse baseline prognostic factors.Among the patients surviving beyond 24 months and with PD-L1 status available, (17/20) 85% had baseline PD-L1 tumor proportion scores (TPS) below 50% (a population typically less responsive to ICI), supporting the potential of aglatimagene to upregulate PD-L1 in the tumor microenvironment and convert
- SECSEC Form S-8 filed by Candel Therapeutics Inc.S-8 - Candel Therapeutics, Inc. (0001841387) (Filer)
- SECSEC Form 10-K filed by Candel Therapeutics Inc.10-K - Candel Therapeutics, Inc. (0001841387) (Filer)
- SECCandel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
- PRCandel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate HighlightsCompany plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026Company plans to submit a Biologics License Application (BLA) for aglatimagene in localized, intermediate-to high-risk prostate cancer in Q4 2026Company announced investigational new drug (IND) clearance for linoserpaturev (CAN-3110) in recurrent high-grade glioma (rHGG) to support enabling work for a potential future randomized controlled phase 2 dose regimen finding study.Entered into a $130 million term loan facility with Tri
CADL FAQ
7 questionsWhat does Candel Therapeutics Inc. do?
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate...Where does CADL stock trade?
Candel Therapeutics Inc. (CADL) is listed on NASDAQ.What sector and industry is CADL in?
Candel Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Candel Therapeutics Inc. go public?
Candel Therapeutics Inc. (CADL) completed its IPO in 2021.What are analysts saying about CADL?
Candel Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-04-20. Recent price targets range from $700.00 to $2500.00.What companies are similar to CADL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CADL side-by-side with any of them on Quantisnow.How can I track CADL on Quantisnow?
Quantisnow aggregates Candel Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CADL to receive live email and push alerts on every new disclosure.